Pfizer (PFE) Given a $41.00 Price Target at Morgan Stanley
Morgan Stanley set a $41.00 price target on Pfizer (NYSE:PFE) in a research report sent to investors on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
PFE has been the topic of a number of other reports. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Tuesday, October 10th. ValuEngine raised shares of Pfizer from a hold rating to a buy rating in a research note on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a buy rating to a hold rating in a research note on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, October 11th. Finally, Barclays set a $38.00 price objective on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. Pfizer has a consensus rating of Buy and an average target price of $38.88.
Shares of Pfizer (PFE) traded down $0.41 on Friday, hitting $36.45. 18,941,200 shares of the stock traded hands, compared to its average volume of 14,690,800. Pfizer has a 12 month low of $30.90 and a 12 month high of $37.35. The company has a market capitalization of $217,270.00, a PE ratio of 22.36, a PEG ratio of 2.46 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.61 earnings per share. sell-side analysts forecast that Pfizer will post 2.59 EPS for the current year.
Pfizer announced that its Board of Directors has authorized a share repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.73%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 78.53%.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last 90 days. Company insiders own 0.06% of the company’s stock.
Several large investors have recently modified their holdings of PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the second quarter worth $103,000. D. Scott Neal Inc. raised its stake in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in Pfizer during the second quarter worth $120,000. Finally, Americafirst Capital Management LLC bought a new position in Pfizer during the third quarter worth $127,000. Institutional investors own 69.74% of the company’s stock.
WARNING: “Pfizer (PFE) Given a $41.00 Price Target at Morgan Stanley” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/pfizer-pfe-given-a-41-00-price-target-at-morgan-stanley/1798812.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.